CORC

在结果中检索

CORC

浏览/检索结果: 共24条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 会议论文
作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Syrigos, K.;  Lee, K. H.
收藏  |  浏览/下载：10/0  |  提交时间：2019/12/05
CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non- small cell lung cancer (EMERGING): A randomised study 会议论文
作者:  Zhong, W-Z.;  Wu, Y-L.;  Chen, K-N.;  Chen, C.;  Gu, C-D.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
CTONG 1103: Erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non- small cell lung cancer (EMERGING): A randomised study 会议论文
作者:  Zhong, W-Z.;  Wu, Y-L.;  Chen, K-N.;  Chen, C.;  Gu, C-D.
收藏  |  浏览/下载：9/0  |  提交时间：2019/11/19
MiR-19b Involved in Pancreatic Cancer Cells Resistance to Erlotinib and Associated with a Poor Prognosis in Pancreatic Cancer 会议论文
Owen Wangensteen Scientific Forum / Annual Clinical Congress of the American-College-of-Surgeons (ACS), OCT 21-25, 2018
作者:  Xu, Jianwei;  Zhan, Hanxiang;  Wang, Lei
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/31
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 会议论文
作者:  Li, W.;  Gadgeel, S. M.;  Soria, J. C.;  Felip, E.;  Cobo, M.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers 会议论文
作者:  Isla, Dolores;  Min, Young Joo;  Ardizzoni, Andrea;  Gadgeel, Shirish;  Dupuis, Nicholas
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib 会议论文
作者:  Liu, Fatao;  Zhou, Yi;  Zhou, Zhen;  Liu, Yun;  Chen, Zhiwei
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutation. 会议论文
作者:  Xing, Ligang;  Wu, Gang;  Wang, Lvhua;  Li, Jian-Cheng;  Wang, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA EGFR Mutant NSCLC Patients 会议论文
作者:  Yue, D.;  Xu, S.;  Wang, Q.;  Li, X.;  Shen, Y.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating m 会议论文
JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20
作者:  Xing, Ligang;  Wu, Gang;  Wang, Lvhua;  Li, Jian-Cheng;  Wang, Jianhua
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/04

©版权所有 ©2017 CSpace - Powered by CSpace